Učitavanje...

Therapeutic Response of Metastatic Colorectal Cancer Harboring a KRAS Missense Mutation After Combination Chemotherapy With the EGFR Inhibitor Panitumumab

Over the past decade, subset analyses of retrospective and prospective clinical studies have determined that KRAS-mutated metastatic colorectal cancers do not respond effectively to inhibition of epidermal growth factor receptor (EGFR) with the EGFR-targeting monoclonal antibodies cetuximab or panit...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:J Natl Compr Canc Netw
Glavni autori: Lou, Emil, D’Souza, Donna, Nelson, Andrew C.
Format: Artigo
Jezik:Inglês
Izdano: 2017
Teme:
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6295659/
https://ncbi.nlm.nih.gov/pubmed/28404754
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!